Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Head & Neck 1

Conditions

Breast Neoplasms 219Neoplasms 15Neoplasm Metastasis 12Carcinoma, Intraductal, Noninfiltrating 10Breast Neoplasms, Male 7Breast Diseases 7Breast Carcinoma In Situ 7Advanced Breast Cancer 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Endometrial Neoplasms 5Neoplasms by Site 3Breast Cancer Metastatic 3Uterine Cervical Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasm Female 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Seizures 1Sarcoma 1Recurrence 1Quality of Life 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteoporosis 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1

Interventions

Cisplatin 178Paclitaxel 79Radiotherapy 76Carboplatin 70Brachytherapy 69pembrolizumab 63Bevacizumab 40Gemcitabine 28Radiation 27Topotecan 26Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 25Nivolumab 22Colposcopy 22human papillomavirus vaccine, L1 type 16, 18 21Magnetic Resonance Spectroscopy 21Drug Therapy 20atezolizumab 19Platinum 19Papillomavirus Vaccines 18Radiotherapy, Intensity-Modulated 17Docetaxel 17Taxes 16Cyclophosphamide 16Biopsy 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14Blood Specimen Collection 14fludarabine 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Uterine Cervical Neoplasms × Anastrozole × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡